Expert Review of Pharmacoeconomics & Outcomes Research最新文献_第9页

Advancing the economics of prevention: emerging methods and approaches. 推进预防经济学：新方法和途径。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-11-01 Epub Date: 2025-10-07 DOI: 10.1080/14737167.2025.2570689

Sabine E Grimm, Ghislaine van Mastrigt, Mickaël Hiligsmann

{"title":"Advancing the economics of prevention: emerging methods and approaches.","authors":"Sabine E Grimm, Ghislaine van Mastrigt, Mickaël Hiligsmann","doi":"10.1080/14737167.2025.2570689","DOIUrl":"10.1080/14737167.2025.2570689","url":null,"abstract":"Introduction: There is global consensus on the critical role of prevention in improving population health and reducing long-term healthcare costs. However, investment in prevention remains comparatively limited. With governments increasingly prioritizing prevention, this may be poised to change.Areas covered: To estimate the economic value of preventive health technologies and support their prioritization for a sustainable healthcare system, we propose three essential themes for economic evaluation: recognizing the value of prevention, estimating its uncertain benefits, and enabling system-level change. We outline key objectives within each theme and highlight emerging methods and approaches to address them.Expert opinion: The key challenge ahead lies in translating these methodological advancements into policy-relevant evidence that supports effective and sustainable prevention strategies. By integrating interdisciplinary perspectives and advancing economic evaluation approaches, we can help ensure prevention receives the recognition and investment needed to foster healthier, more resilient societies.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1255-1262"},"PeriodicalIF":1.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145231737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands. cenobamate治疗荷兰耐药局灶性癫痫患者的成本-效果分析

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-11-01 Epub Date: 2025-08-10 DOI: 10.1080/14737167.2025.2542280

Nannan Li, Marian Majoie, Silvia Evers, Kim Rijkers, Felix Gubler, Rob Rouhl, Richard Lazeron, Pim Klarenbeek, Vicki Laskier-Owens, Mickaël Hiligsmann

{"title":"Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands.","authors":"Nannan Li, Marian Majoie, Silvia Evers, Kim Rijkers, Felix Gubler, Rob Rouhl, Richard Lazeron, Pim Klarenbeek, Vicki Laskier-Owens, Mickaël Hiligsmann","doi":"10.1080/14737167.2025.2542280","DOIUrl":"10.1080/14737167.2025.2542280","url":null,"abstract":"Objective: To assess the cost-effectiveness of cenobamate in epileptic people with focal seizures in the Netherlands.Methods: A Markov model was used to simulate lifetime costs and quality-adjusted life years (QALYs) for cenobamate compared to perampanel, brivaracetam, and lacosamide from the Dutch societal perspective. Data from a randomized controlled trial and open-label extension were used to determine the transition probability, efficacy and safety of treatment with cenobamate. Treatment, administration, routine monitoring, seizure event management, adverse events and productivity costs were included. Both one-way and probabilistic sensitivity analyses were conducted to explore the uncertainty.Results: Cenobamate was associated with an average total cost of €466,560 and 9.922 QALY gained. Among the four drugs tested, treatment with cenobamate indicated lowest cost and highest QALY gained, suggesting cenobamate dominates all comparators. One-way sensitivity analysis confirms the robustness of our results. Probabilistic sensitivity analyses revealed that at the willingness to pay threshold of €50,000/QALY, the probability that cenobamate is cost-effective was 100%.Conclusion: With the acknowledgment of the limitations, we concluded that cenobamate is less costly and more effective, which can be considered a cost-effective treatment option for patients with drug-resistant focal seizures in the Netherlands. Future real-world data are needed to confirm our findings.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1323-1335"},"PeriodicalIF":1.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain. 西班牙无防腐剂拉坦诺前列素与无防腐剂拉坦诺前列素阳离子乳剂治疗开角型青光眼和高眼压的成本-效用分析。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-11-01 Epub Date: 2025-09-08 DOI: 10.1080/14737167.2025.2556693

María Isabel Canut, Julián García-Feijoo, Jose Manuel Larrosa-Poves, Fernando López-López, Marta Pazos, Nataly Espinoza-Cámac, Itziar Oyagüez, Teresa Del Rio, Maria Rodríguez

{"title":"Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain.","authors":"María Isabel Canut, Julián García-Feijoo, Jose Manuel Larrosa-Poves, Fernando López-López, Marta Pazos, Nataly Espinoza-Cámac, Itziar Oyagüez, Teresa Del Rio, Maria Rodríguez","doi":"10.1080/14737167.2025.2556693","DOIUrl":"10.1080/14737167.2025.2556693","url":null,"abstract":"Background: This study evaluated the efficiency CE-latanoprost unidose (cationic emulsion of latanoprost) versus latanoprost unidose (non-emulsion formulation) in open-angle glaucoma and ocular hypertension (OAG/OHT) with concomitant ocular surface disease (OSD) patients' treatment in Spain.Methods: A cost-utility analysis was performed using a Markov model simulating the progression of OAG/OHT. From a Spanish National Health System perspective over a 5-year time horizon, quality-adjusted life years (QALYs) and the total cost of each therapy were estimated (annual discount rate: 3%). Therapy efficacy included adherence, disease progression, and OSD reduction. Utility values for OAG/OHT and OSD-related disutility values were obtained from literature. Five ophthalmologists validated all included parameters. Total costs (€, 2023) included CE-latanoprost or latanoprost drug acquisition (€10/30 single-dose), glaucoma diagnosis, patient follow-up, and OAG management costs.Results: The base case results showed that CE-latanoprost unidose increased health outcomes (2.69 vs. 2.49 QALYs) and lowered costs (€5,292.12 vs. €5,441.55) being a dominant option (0.21 QALYs gained and €149.43 less) compared to latanoprost unidose.Conclusions: CE-latanoprost unidose was a cost-effective option for the treatment of patients with OAG/OHT and OSD in comparison to latanoprost unidose (non-emulsion formulation). In addition to its clinical benefits, the economic analysis supports using CE-latanoprost in terms of efficiency.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1337-1343"},"PeriodicalIF":1.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144991856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and Shiga prefecture. 20价肺炎球菌结合疫苗对日本和滋贺县66-84岁成人的健康和经济影响

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-11-01 Epub Date: 2025-07-28 DOI: 10.1080/14737167.2025.2519755

Tomoyuki Suzuki, Yoko Hirano, Kazumasa Kamei, Kayoko Miyata, Masahiro Kusama, Piotr Karwala, Camille Moyon, Catriona Crossan, Shuhei Ito, Jeffrey Vietri, Fumihiko Kakuno

{"title":"Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66-84 years in Japan and Shiga prefecture.","authors":"Tomoyuki Suzuki, Yoko Hirano, Kazumasa Kamei, Kayoko Miyata, Masahiro Kusama, Piotr Karwala, Camille Moyon, Catriona Crossan, Shuhei Ito, Jeffrey Vietri, Fumihiko Kakuno","doi":"10.1080/14737167.2025.2519755","DOIUrl":"10.1080/14737167.2025.2519755","url":null,"abstract":"Background: The Japanese National Immunization Program against pneumococcal disease (PD) includes 23-valent pneumococcal polysaccharide vaccine (PPSV23) but does not provide vaccination for adults aged ≥66 years. We evaluated the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged 66-84 years with no history of PPSV23 vaccination in Japan and assessed the potential economic and health impact of introducing PCV20 on the local government (specifically, Shiga prefecture).Research design and methods: Using a Markov model, we assessed lifetime costs, quality-adjusted life-years (QALYs), and number of prevented cases and deaths caused by PD.Results: In national-level analysis, PCV20 was cost-effective compared with no vaccination under incremental cost-effectiveness ratio threshold of Japanese yen (JPY) 5,000,000/QALY, i.e. JPY1,677,401/QALY and JPY1,351,811/QALY from payer and societal perspectives, respectively. PCV20 was dominant (less costly and more effective) compared with PPSV23. In local-level analysis, the introduction of PCV20 required initial costs but resulted in greater cost savings related to medical expenses (-JPY424 and -JPY430 per person) and nursing care (-JPY560 and -JPY575 per person) compared to PPSV23 and no vaccination, respectively.Conclusions: PCV20 is cost-effective compared with PPSV23 and no vaccination in adults aged 66-84 years, which could reduce the future healthcare burden in Japan.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1309-1322"},"PeriodicalIF":1.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preference research is underutilized in health prevention. 偏好研究在健康预防方面未得到充分利用。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-11-01 Epub Date: 2025-08-17 DOI: 10.1080/14737167.2025.2548279

Brett Hauber, Mickael Hiligsmann

引用次数: 0

Cost-effectiveness of MRI strategies for early prostate cancer detection: a systematic review. 早期前列腺癌MRI检测策略的成本效益：一项系统综述。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-11-01 Epub Date: 2025-08-07 DOI: 10.1080/14737167.2025.2543464

Asal Sadat Niaraees Zavare, Atefeh Najafi Shahkoohi, Farhad Khalili, Aziz Rezapour, Somayeh Afshari, Samira Alipour, Ali Sarabi Asiabar

{"title":"Cost-effectiveness of MRI strategies for early prostate cancer detection: a systematic review.","authors":"Asal Sadat Niaraees Zavare, Atefeh Najafi Shahkoohi, Farhad Khalili, Aziz Rezapour, Somayeh Afshari, Samira Alipour, Ali Sarabi Asiabar","doi":"10.1080/14737167.2025.2543464","DOIUrl":"10.1080/14737167.2025.2543464","url":null,"abstract":"Objectives: The objective of this study is to evaluate the cost-effectiveness of different Magnetic Resonance Imaging strategies for the early detection of prostate cancer.Methods: A comprehensive search was conducted up to 15 December 2024, utilizing databases such as PubMed and Scopus. The focus was on full economic evaluations, excluding non-English articles and reviews. The quality of the studies was assessed using the QHES checklist. The following data were extracted: settings, interventions, populations, types of economic evaluations, health outcomes, costs, and ICERs.Results: Of the 110 articles that were assessed, 9 were selected for qualitative analysis, resulting in an overall high-quality score. The findings demonstrated that the range of MRI costs applied differed across countries. While the financial implications of non-screening are comparatively lower, the effectiveness of using screening strategies for early detection of cancer is superior to that of non-screening. Specifically, MRI was found to be more cost-effective than conventional methods. The utilization of MRI prior to biopsy has the potential to reduce unnecessary procedures while enhancing clinical cancer detection.Conclusion: The economic viability of integrating advanced MRI techniques into prostate cancer screening is demonstrated, leading to enhanced patient outcomes by facilitating early detection and minimizing overtreatment.Registration: PROSPERO (CRD42024572261).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1263-1276"},"PeriodicalIF":1.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review of methodological aspects of economic evaluations used in NICE assessments for treatments in metastatic breast cancer. 对转移性乳腺癌治疗的NICE评估中使用的经济评估的方法学方面的回顾。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-01 Epub Date: 2025-07-27 DOI: 10.1080/14737167.2025.2537191

Jeroen Hendrikus Jacobus Paulissen, Sharon Wolters, Arjan Jacobus Postma, Niels Jacobus Postma, Maarten Jacobus Postma, Marinus van Hulst

{"title":"A review of methodological aspects of economic evaluations used in NICE assessments for treatments in metastatic breast cancer.","authors":"Jeroen Hendrikus Jacobus Paulissen, Sharon Wolters, Arjan Jacobus Postma, Niels Jacobus Postma, Maarten Jacobus Postma, Marinus van Hulst","doi":"10.1080/14737167.2025.2537191","DOIUrl":"10.1080/14737167.2025.2537191","url":null,"abstract":"Introduction: Methodological choices need to be made during model development. These choices can influence the outcome of a National Institute for Health and Care Excellence (NICE) assessment.Areas covered: This review aims to identify, assess, and describe possible trends within the methodological aspects of economic evaluations used in NICE assessments of treatments for metastatic breast cancer (mBC). The NICE website was searched to identify technology appraisals submitted between 1 January 2009, and 31 December 2023. In this review methodological aspects are analyzed and discussed in three clusters - input data, model settings, and model outcomes - across the following characteristics: clinical trial information, quality-of-life measures, treatments used, model structure, health states, time horizon, threshold applied, and the NICE recommendations. This review provides a reference for stakeholders who want to understand previous NICE assessments of treatments for mBC, and the settings used in those, which can optimize decisions during model development.Expert opinion: Uniformity in the methodological choices made during model development and the economic evaluations can increase transparency, increase comparability, and reduce complexity of the NICE assessment.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1149-1157"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The economic benefits of fracture prevention. 预防骨折的经济效益。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-01 Epub Date: 2025-07-28 DOI: 10.1080/14737167.2025.2539838

Lakshmi Nagendra, Manju Chandran, Mickael Hiligsmann

{"title":"The economic benefits of fracture prevention.","authors":"Lakshmi Nagendra, Manju Chandran, Mickael Hiligsmann","doi":"10.1080/14737167.2025.2539838","DOIUrl":"10.1080/14737167.2025.2539838","url":null,"abstract":"Introduction: Osteoporosis-related fractures represent a significant and growing public health concern, especially in aging populations. Despite the availability of effective treatments, significant care gaps persist in both primary and secondary prevention.Areas covered: This narrative review synthesizes key findings from economic evaluations examining the cost-effectiveness of pharmacological and non-pharmacological therapies, fracture liaison services (FLS), and FRAX®-based intervention thresholds. Relevant literature was reviewed, including systematic reviews, country specific studies, and emerging data on novel technologies. The evidence consistently demonstrates that fracture prevention strategies are cost-effective across diverse healthcare settings. Pharmacological monotherapy and sequential regimens have shown favorable economic profiles, while FLS programs, although resource-intensive, significantly reduce re-fracture rates and associated costs. Intervention thresholds should be derived clinically, with health economic modeling used to evaluate their cost-effectiveness so as to guide rational, risk-based treatment strategies.Expert opinion: Health economic evaluations are increasingly enabling the development of osteoporosis treatment strategies, highlighting the strong cost-effectiveness potential of these interventions. However, challenges remain including heterogeneity in analytical approaches, under-representation of low- and middle-income countries, and limited incorporation of real-world (adherence) data. Maintaining methodological consistency, expanding region-specific data, and evaluating emerging technologies with robust economic frameworks are essential steps toward achieving globally equitable and cost-effective osteoporosis care.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1143-1148"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis. 保加利亚患者一线奥西替尼有效性的真实世界证据：回顾性分析。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-01 Epub Date: 2025-07-20 DOI: 10.1080/14737167.2025.2535636

Manoela Manova, Boryana Ivanova, Jeliazko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Zornitsa Katrandzhieva, Lyubomir Bakalivanov, Boryana Zidarova, Dimitrina Apostolova, Mariya Vasileva, Silvia Terezova, Alexandra Savova

{"title":"Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis.","authors":"Manoela Manova, Boryana Ivanova, Jeliazko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Zornitsa Katrandzhieva, Lyubomir Bakalivanov, Boryana Zidarova, Dimitrina Apostolova, Mariya Vasileva, Silvia Terezova, Alexandra Savova","doi":"10.1080/14737167.2025.2535636","DOIUrl":"10.1080/14737167.2025.2535636","url":null,"abstract":"Background: Third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) osimertinib is approved as a first-line treatment against non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. Herein, we perform a retrospective analysis of real-world data on first-line osimertinib treatment among Bulgarian patients with NSCLC, comparing treatment outcomes to FLAURA results.Research design and methods: Patient data were obtained from electronic health records over a 4-year period. Baseline characteristics and endpoints (progression-free survival [PFS], objective response rate [ORR], and clinical benefit rate [CBR]) were compared. Iterative proportional fitting was performed to balance patient characteristics prior to survival analysis.Results: A total of 365 patients on first-line osimertinib were included. Partial responses were more frequent in the RWE cohort (24% vs 13%), while the opposite was noted for stable disease (63% vs 80%). Complete response frequency was comparable (2% vs 1%). The ORR was higher in the real world compared to in FLAURA (26% vs 14%), whereas CBR was slightly higher in the trial (89% vs 94%). The real-world PFS was higher than reported in FLAURA (19.1 vs 18.9 months), with more favorable outcomes in the RWE cohort beyond 18 months.Conclusion: RWE closely aligns with FLAURA results, suggesting even greater benefit of first-line osimertinib in the real-world setting.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1231-1237"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intersectoral costs of pneumococcal diseases: a systematic review of partial economic evaluation studies. 肺炎球菌疾病的部门间成本：对部分经济评估研究的系统回顾。

IF 1.5 4区医学

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2025-10-01 Epub Date: 2025-08-03 DOI: 10.1080/14737167.2025.2542285

Emad Almomani, Ingeborg Maria van der Putten, Ghislaine van Mastrigt, Darin Elabbasy, Adnan Al-Lahham, Aggie Paulus

{"title":"Intersectoral costs of pneumococcal diseases: a systematic review of partial economic evaluation studies.","authors":"Emad Almomani, Ingeborg Maria van der Putten, Ghislaine van Mastrigt, Darin Elabbasy, Adnan Al-Lahham, Aggie Paulus","doi":"10.1080/14737167.2025.2542285","DOIUrl":"10.1080/14737167.2025.2542285","url":null,"abstract":"Introduction: This systematic review explores the intersectoral costs associated with pneumococcal diseases across different age groups and related impacts on societal costs.Methods: Four databases were searched (1990-2023) for partial economic evaluation studies of pneumococcal diseases from a societal perspective. The identified intersectoral costs were presented narratively and in tabular form. Studies were appraised on quality, and the PRISMA guidelines were followed.Results: Twenty-four studies were included with wide variation in types of analysis. Intersectoral costs were captured in five sectors: patient/family, paid labor, opportunity costs, education, and public/social services. Paid labor was the main sector considered in the included studies, followed by patient/family. Cost bearers varied according to patients' age group. Mean annual costs per child varied from $182 to $82,217 healthcare costs, $240 to $846 patient/family costs and $654 to $25,721 productivity cost. In adults, mean annual costs of $168 to $43,676 healthcare costs, and $23 to $33,149 productivity costs were reported.Conclusions: Intersectoral costs associated with pneumococcal diseases vary widely and appear in several sectors. More cost-of-illness studies are needed with wider perspectives, particularly in developing countries, to understand true economic costs of pneumococcal diseases and support the endeavor of informing a decision on treatment/preventive strategies.Registration: PROSPERO (CRD42023417042).","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1195-1210"},"PeriodicalIF":1.5,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0